<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Meme kanseri tedavisi &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/meme-kanseri-tedavisi/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 22 Jan 2026 22:21:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Meme kanseri tedavisi &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>BLU-222 Boosts CDK4/6 Inhibitors in Resistant Breast Cancer</title>
		<link>https://bioengineer.org/blu-222-boosts-cdk4-6-inhibitors-in-resistant-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 22:21:44 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[BLU-222]]></category>
		<category><![CDATA[CDK4 ve CDK6 inhibitörlerini kapsar. 2.]]></category>
		<category><![CDATA[İlaç direnci]]></category>
		<category><![CDATA[İşte bu içerik için uygun 5 etiket: **CDK inhibitörleri]]></category>
		<category><![CDATA[Kombinasyon tedavisi** **Kısa Açıklama:** 1. **CDK inhibitörleri:** Makalenin ana konusu olan CDK2]]></category>
		<category><![CDATA[Meme kanseri tedavisi]]></category>
		<guid isPermaLink="false">https://bioengineer.org/blu-222-boosts-cdk4-6-inhibitors-in-resistant-breast-cancer/</guid>

					<description><![CDATA[In a groundbreaking development in the battle against breast cancer, researchers have unveiled a novel therapeutic strategy that could redefine treatment paradigms, especially in drug-resistant forms of the disease. The study, led by Luo, Wang, Bui, and colleagues, focuses on a potent CDK2 inhibitor, BLU-222, which demonstrates remarkable synergy when combined with existing CDK4/6 inhibitors. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319508</post-id>	</item>
	</channel>
</rss>
